Crizotinib, a tyrosine kinase inhibitor that targets both ALK and MET tyrosine kinases, was originally developed as a MET-specific inhibitor but has been FDA-approved for use in ALK-positive NSCLC. The gene discussed is MET; the disease is non-small cell lung carcinoma.